Disclosed are compounds and methods for treating tauopathy.

Disclosed are compounds and methods for treating tauopathy.

Compounds of formula I:

##STR00001##

are disclosed, as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disorders in a patient in need are also disclosed. Such disorders include depression, bipolar disorder, pain, schizophrenia, obsessive compulsive disorder, addiction, social disorder, attention deficit hyperactivity disorder, an anxiety disorder, autism, a cognitive impairment, or a neuropsychiatric symptom such as apathy, depression, anxiety, psychosis, aggression, agitation, impulse control disorders, and sleep disorders in neurological disorders such as Alzheimer's and Parkinson's diseases.

Compounds of formula I:

##STR00001##

are disclosed, as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disorders in a patient in need are also disclosed. Such disorders include depression, bipolar disorder, pain, schizophrenia, obsessive compulsive disorder, addiction, social disorder, attention deficit hyperactivity disorder, an anxiety disorder, autism, a cognitive impairment, or a neuropsychiatric symptom such as apathy, depression, anxiety, psychosis, aggression, agitation, impulse control disorders, and sleep disorders in neurological disorders such as Alzheimer's and Parkinson's diseases.

The present invention relates to a leveling agent and electroplating composition comprising the same. When features are plated using the electroplating composition of the present invention, excellently leveled plated surfaces with minimized defects may be obtained.

The present invention relates to a leveling agent and electroplating composition comprising the same. When features are plated using the electroplating composition of the present invention, excellently leveled plated surfaces with minimized defects may be obtained.

A cyclohexane derivative as shown by formula IB or a stereoisomer or a salt thereof, has a high affinity for D.sub.3 receptors and 5-hydroxytryptamine, has a lower affinity for D.sub.2 receptors, shows a high selectivity for D.sub.3/D.sub.2 receptors, and can be used as a therapeutic drug against neuropsychiatric diseases. ##STR00001##
wherein; X is N or CH; R is ##STR00002##
R is optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I and C.sub.1-C.sub.6 alkyl; and the C.sub.1-C.sub.6 alkyl is optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, and I.

A cyclohexane derivative as shown by formula IB or a stereoisomer or a salt thereof, has a high affinity for D.sub.3 receptors and 5-hydroxytryptamine, has a lower affinity for D.sub.2 receptors, shows a high selectivity for D.sub.3/D.sub.2 receptors, and can be used as a therapeutic drug against neuropsychiatric diseases. ##STR00001##
wherein; X is N or CH; R is ##STR00002##
R is optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I and C.sub.1-C.sub.6 alkyl; and the C.sub.1-C.sub.6 alkyl is optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, and I.

Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, or pharmaceutically acceptable salts thereof, compositions thereof, and methods of their use.

##STR00001##

Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, or pharmaceutically acceptable salts thereof, compositions thereof, and methods of their use.

##STR00001##